Clinical Trial

A Study of BL-B01D1 and Almonertinib in Patients With Resectable EGFR+ Stage II-IIIB NSCLC

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This is a Phase II, open-labeled, single-arm, study of neoadjuvant BL-B01D1in combination with Almonertinib followed by adjuvant Almonertinib for the treatment of Patients with EGFR-Mutation Positive Stage II-IIIB Resectable Non-Small Cell Lung Cancer.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-04-23.
Status change: Not Yet Recruiting → Recruiting 2025-07-17
Trial Details
NCT Number NCT06951464
Lead Sponsor Sichuan University
Conditions Non-Small Cell Lung Cancer
Enrollment 40 participants
Start Date 2025-06-25
Primary Completion 2027-05-05 (estimated)
Study Completion 2029-03-05 (estimated)
Updated on ClinicalTrials.gov 2025-07-23